Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5052W HIGH $1.63
Volume
2.51 M
Value Traded
628.71 K
Short % Float
8.01%
+3.63%Week
-20.83%1 Month
-34.99%3 Month
-43.47%6 Month
-91.61%5 Year
-91.61%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
132.13 M
EPS (TTM)
-0.27
P/E Ratio
-
Ent. Value
98.72 M
Total Shares
203.24 M
Float Shares
160.15 M
Insiders
21.20%
Institutions
30.71%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LUCD Catalyst Timeline
Dated clinical, regulatory and corporate events for Lucid Diagnostics Inc.
Past FDA Catalysts and PDUFA Decisions
How LUCD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Lucid Diagnostics Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every LUCD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| EsoGuard | Barrett's esophagus | 2025-12-09 | technical success rate: 95%; cell collection time: under two minutes; patient population: 11,991Read More | Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer DetectionRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Matheis DennisDirector | Buy | 245,000 1,033,443 held | $1.00 | 05/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LUCD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LUCD for Q2 2026. | ||||
LUCD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LUCD ranks across every disease it competes in
Competitive Position is a premium feature
See how LUCD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLUCD News
LUCD▲ +5.6%on this news
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
Lucid Diagnostics has made significant progress in payment, billing, and coding pathways for its EsoGuard and EsoCheck products. The Medicare Advisory Panel recommended maintaining the original payment basis for EsoGuard, while a new CPT code for EsoCheck was approved. Additionally, a proposed ICD-10-CM diagnosis code for positive EsoGuard results received favorable feedback from the CDC/NCHS committee.
Read more →LUCDLucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Lucid Diagnostics reported a revenue of $1.5 million for the second quarter of 2026, driven by the processing of 2,770 EsoGuard tests. The company secured a commercial coverage policy for EsoGuard, enhancing its market position. However, it also reported significant operating expenses and a net loss of approximately $14.7 million, indicating ongoing financial challenges.
Read more →LUCDLucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
Lucid Diagnostics has secured a positive commercial coverage policy for its EsoGuard® Esophageal DNA Test from Concert, effective July 2026. This policy recognizes EsoGuard as the only esophageal precancer test meeting necessary criteria and cites strong clinical evidence for its necessity in at-risk patients. The adoption by multiple health plans signifies a step towards broader access to this crucial screening tool.
Read more →LUCDLucid Diagnostics to Participate in Upcoming Investor Conferences
Lucid Diagnostics Inc. will participate in several upcoming investor conferences, including the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference and the Canaccord Genuity 46th Annual Growth Conference. The company is focused on cancer prevention, particularly for patients at risk of esophageal cancer due to gastroesophageal reflux disease (GERD). Their EsoGuard® Esophageal DNA Test is designed for early detection of precancerous conditions.
Read more →LUCDLucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
Lucid Diagnostics Inc. will host a business update conference call and webcast on August 13, 2026, at 8:30 AM ET. CEO Lishan Aklog and CFO Dennis McGrath will discuss the company's operations, growth strategy, and second quarter financial results. The event aims to provide investors with insights into the company's performance and future direction.
Read more →LUCDLucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
Lucid Diagnostics Inc. provided a business update and reported its first quarter 2026 financial results, processing 3,177 EsoGuard tests and generating $1.3 million in revenue. The company holds $45 million in proforma cash, allowing for extended operations into 2027. The chairman expressed strong confidence in achieving Medicare coverage, which remains a crucial milestone for the company. However, Lucid reported substantial operating expenses and net losses during the quarter.
Read more →LUCDLucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
Lucid Diagnostics Inc. will hold a business update conference call on May 14, 2026, at 8:30 AM ET. CEO Lishan Aklog will discuss the company's operations and growth strategy, while CFO Dennis McGrath will present the first quarter 2026 financial results. The call will be accessible via webcast and telephone.
Read more →LUCDLucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
Lucid Diagnostics has successfully closed an underwritten offering of 18 million common shares, raising approximately $18 million. The offering was supported by a significant investment from an institutional investor. The funds will be utilized for working capital and general corporate purposes, as the company continues to focus on cancer prevention diagnostics.
Read more →LUCD▼ -16.8%on this newsshared move
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
Lucid Diagnostics has announced a registered direct offering of 18 million common shares at $1.00 each, aiming to raise about $18 million. The offering is backed by a $15 million investment from a fundamental institutional investor. Proceeds will be used for working capital and general corporate purposes, with the closing expected on April 24, 2026.
Read more →LUCDLucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
Lucid Diagnostics Inc. will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026. CEO Lishan Aklog will lead the discussion, which will be available for live streaming and archived for later viewing. The company specializes in cancer prevention diagnostics, particularly for patients at risk of esophageal cancer.
Read more →LUCDLucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Lucid Diagnostics provided a business update and reported its financial results for Q4 and full year 2025, highlighting a revenue of $1.5 million. The company expanded access to its EsoGuard test through a contract with the U.S. Department of Veterans Affairs and presented positive data on esophageal precancer detection. Future priorities include deepening relationships with health systems and securing Medicare coverage.
Read more →LUCDLucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026
Lucid Diagnostics Inc. will hold a business update conference call on March 26, 2026, at 8:30 AM ET. CEO Lishan Aklog and CFO Dennis McGrath will discuss the company's operations and fourth quarter 2025 financial results. The event will be accessible via webcast and telephone for investors.
Read more →LUCD▼ -6.6%on this news
Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®
Lucid Diagnostics has secured a contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. This contract will enhance access to esophageal precancer testing for over nine million veterans annually. The agreement allows VA facilities to procure EsoGuard at Medicare rates, reflecting confidence in the test's clinical evidence.
Read more →LUCDLucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
Lucid Diagnostics has announced positive data from the largest real-world study on esophageal precancer detection, involving nearly 12,000 patients. The study highlights the effectiveness of the EsoGuard Esophageal DNA Test and EsoCheck device, showcasing a 95% technical success rate and rapid cell collection. The findings support the tools' utility in non-invasive screening for Barrett's esophagus.
Read more →LUCDLucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
Lucid Diagnostics has been named a top-ranking honoree in the GenomeWeb 2025 Best Places to Work program, recognized for its positive workplace culture and commitment to employee development. The company, which specializes in cancer prevention diagnostics, emphasizes a culture of collaboration and service to patients. This accolade reflects the dedication of Lucid's team to uphold high standards in their work.
Read more →LUCDLucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics Inc. will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025, in New York City. CFO Dennis McGrath will be available for one-on-one investor meetings. Lucid focuses on cancer prevention through its EsoGuard® Esophageal DNA Test, aimed at patients at risk of esophageal precancer.
Read more →LUCD▲ +6.7%on this newsshared move
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
Lucid Diagnostics reported a positive business update for Q3 2025, processing 2,841 EsoGuard tests and generating $1.2 million in revenue. The company ended the quarter with over $47 million in cash, extending its financial runway through 2026. A recent Medicare advisory committee meeting yielded unanimous support for EsoGuard coverage, bolstering the company's commercialization efforts.
Read more →LUCDLucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
Lucid Diagnostics Inc. will hold a business update conference call on November 12, 2025, at 8:30 AM ET. CEO Lishan Aklog will provide insights into the company's operations and growth strategy, while CFO Dennis McGrath will discuss the third quarter financial results. The call will be accessible via telephone and webcast.
Read more →LUCD▲ +5.9%on this news
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit
Lucid Diagnostics Inc. will participate in the 2025 Maxim Growth Summit on October 22-23 in New York City. CFO Dennis McGrath will host one-on-one meetings with investors during the event. The company focuses on cancer prevention, particularly for patients at risk of esophageal cancer due to gastroesophageal reflux disease (GERD).
Read more →LUCDLucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors
Lucid Diagnostics has appointed John R. Palumbo to its Board of Directors, effective September 22, 2025. With 40 years of experience in healthcare, Palumbo's leadership is expected to guide the company through significant growth phases. His prior roles include senior positions at major healthcare organizations, and he aims to help Lucid address critical needs in cancer prevention.
Read more →About Lucid Diagnostics Inc.
Headquarters360 MADISON AVENUE, NEW YORK, NY, 10017
BIOPHARMAWATCH ELITE PLUS
Trade the next LUCD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime